Physician profile
Imran Ahmad
NPI 1538494844
$2,737.35
in general payments reported to CMS, 2019-2025
32 companies · $657 in 2025
The $657 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $196 · 2020: $247 · 2021: $376 · 2022: $116 · 2023: $443 · 2024: $702 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,728 · Education: $73.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.52 |
| Education | $73.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $331.24 | 2022-2025 | |
| Abbvie INC. | $298.02 | 2021-2025 | |
| Astellas Pharma US INC | $249.17 | 2020-2025 | Vyloy |
| Amgen INC. | $243.65 | 2019-2025 | Imdelltra (Amg757), Blincyto, Kyprolis |
| Novartis Pharmaceuticals Corporation | $224.70 | 2022-2025 | |
| Daiichi Sankyo INC. | $160.06 | 2020-2025 | Enhertu, Injectafer |
| Dova Pharmaceuticals | $134.04 | 2020 | |
| Celgene Corporation | $110.27 | 2023-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $104.44 | 2023-2025 | Ojjaara |
| Genzyme Corporation | $100.44 | 2023-2025 | |
| Ethicon US, LLC | $87.96 | 2023-2025 | Echelon Endopath, Enseal, Harmonic |
| Epizyme, INC. | $84.03 | 2021 | |
| Sobi, INC | $75.31 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.38 | 2023-2025 | |
| Genentech USA, INC. | $58.01 | 2024-2025 | Phesgo, Itovebi, Perjeta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $39.95 | 2024 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $38.59 | 2019-2024 | Imfinzi |
| Stemline Therapeutics INC. | $35.81 | 2024-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $35.04 | 2022 | |
| Coherus Oncology, INC. | $29.17 | 2024 | |
| Taiho Oncology, INC. | $26.59 | 2025 | |
| Blueprint Medicines Corporation | $25.90 | 2024 | Ayvakit |
| Janssen Biotech, INC. | $24.13 | 2024 | Rybrevant |
| Puma Biotechnology, INC. | $20.98 | 2024 | |
| Geron Corporation | $18.69 | 2024 | Rytelo |
| Springworks Therapeutics, INC. | $18.01 | 2025 | Ogsiveo |
| Lilly USA, LLC | $18.00 | 2025 | Jaypirca |
| Kyowa Kirin, INC. | $17.45 | 2023 | Poteligeo |
| Cti Biopharma Corp. | $17.11 | 2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $14.23 | 2024 | Ultomiris |
| Boston Scientific Corporation | $13.06 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.